A Novel Adenylyl Cyclase Type 5 Inhibitor That Reduces Myocardial Infarct Size Even When Administered After Coronary Artery Reperfusion

We developed a novel adenylyl cyclase type 5 (AC5) inhibitor, C90, that reduces myocardial infarct size even when administered after coronary reperfusion. This is key, since it is not practical to administer a drug to a patient with myocardial infarction before revascularization, and is one reason w...

Full description

Saved in:
Bibliographic Details
Published in:J Mol Cell Cardiol
Main Authors: Zhang, Jie, Levy, Daniel, Oydanich, Marko, Bravo, Claudio, Yoon, Seonghun, Vatner, Dorothy E., Vatner, Stephen F.
Format: Artigo
Language:Inglês
Published: 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6103820/
https://ncbi.nlm.nih.gov/pubmed/29800555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yjmcc.2018.05.014
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items